min read

The fastest path to better mental health for your employees

Learn why leading employers choose Sleepio & Daylight, digital therapeutics from Big Health, in under 120 days.

Now, more than ever, employers are taking an increasing role in keeping employees healthy — especially when it comes to mental health. However, offering mental health benefits to people who need them most isn’t as straightforward as it may sound.

Big Health is committed to making it easier with Sleepio® and Daylight®: a relatively new class of treatments called digital therapeutics, which can be delivered 24/7 via mobile device that show potential for addressing barriers present within human-delivered care alone. Based on cognitive behavioral therapy (CBT) techniques developed by our industry-leading therapists, Sleepio and Daylight are proven to help people recover from two of the most common mental health conditions, insomnia and anxiety, respectively. Additionally, Big Health is committed to making it simple for companies to select and roll out our digital therapeutics to their populations. By making contracting, outreach, billing, and reporting easier than other digital therapeutics, we’re empowering dozens of employers to implement Sleepio and Daylight for their workers in under 120 days. Here’s how.

We make contracting easy with a simple addendum

One of the hardest parts of bringing new benefits onboard is all the red tape around contracts. Seasoned business leaders are not strangers to contract redlining, security reviews, picking through terms and conditions, securing MSAs and SOWs — all of which can slow down the process of getting employees better benefits.

Bringing digital therapeutics by Big Health — Sleepio for insomnia and Daylight for anxiety —  to an employee population only requires an addendum to the Pharmacy Benefit Manager (PBM) contract. Because we partner directly with PBMs, the due diligence and pricing negotiation has already been completed making it simple for employers to opt in via a two-page form.

We integrate directly with the PBM

Because Big Health integrates with PBMs, there’s virtually no work needed by employers to establish which employees are eligible for the new benefits. The data sharing happens between Big Health and the PBM, automatically marking anyone who’s eligible for pharmacy benefits as also eligible for our digital therapeutics. Additionally, this enables Big Health to identify which employees are experiencing symptoms of anxiety and insomnia based on filled prescriptions, and provide them with proactive access to Sleepio or Daylight.

The PBM integration also powers simple billing. When employees enroll in Sleepio or Daylight, whether it’s through the prescription pathway or seeing outreach communications at work, the cost is billed via claim to the pharmacy budget. This eliminates the need to create an additional vendor bill for approval. It also saves benefits leaders the time of trying to find room in the wellness budget, which is typically much smaller.

We seamlessly identify patients in need

When we offer access to our digital therapeutics to patients who are filling certain mental health prescriptions, that’s our medication assessment™ program in action. This program identifies members  who fill a common mental health medication prescription and offers them immediate access to  Sleepio for insomnia and Daylight for anxiety, as an option alongside their medications.  By identifying the members based on prescription fills, we’re providing care to people who have self-identified as needing help and exhibited motivation to take action for their mental health. That care comes in the form of a safe, effective, non-drug solution that meets the needs of up to 75% of people who prefer a non-drug option when treating a mental health condition.

When one considers the risks of addiction and unsafe side effects that come with the most common drugs for insomnia and anxiety, it’s easy to see why. The benefit to employers is clear as well: Not only do digital therapeutics remove the friction associated with finding and scheduling a live therapist, they also cause fewer side effects like fatigue, nausea, and other safety concerns.

We back our products up with proven clinical results and reporting

While benefits leaders are in the research phase of choosing a solution, our wealth of clinical evidence — including 64 publications, 13 randomized controlled trials (RCTs) with 28k participants, and four clinical guideline citations — provides an apples-to-apples method for comparing Sleepio and Daylight against other digital therapeutics.

Employers that use Big Health products receive insight into just how much benefit their employees are getting through cumulative reports using de-identified data. This information allows benefits leaders to prove to senior leadership that the investment in Sleepio and Daylight is leading to better health and quality of life for employees — which in turn leads to meaningful business impacts.

Get your employees the help they need sooner

The events of the past two years have had a multitude of impacts, but for benefits leaders two things remain top of mind. One: employees need more help than ever before with their mental health. Two: the teams that manage benefits are smaller and busier than ever. At the end of the day, benefits leaders want to do what they can to improve the lives of their employees. While rolling out new programs is time and budget-intensive, Big Health has worked hard to create scalable, accessible turnkey solutions to address the mental health needs of any workforce. Sleepio and Daylight are innovative digital therapeutics that are proven to be safe and effective. Reach out today to learn how you can help your workforce with their mental health.

DOC-1631 Effective 08/2022

Disclaimer: Sleepio and Daylight are available as an adjunct to usual medical care for insomnia disorder or generalized anxiety disorder, respectively, for adults ages 18 and older, without FDA review under their COVID-19 policy.

No items found.

Subscribe to blog

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023